Blog

Goldman Sachs Group is riding a wave of renewed strength in its mergers and acquisitions business, together with substantial asset and wealth management inflows. This momentum, along with solid Q3 earnings, has caught investor attention lately.

See our latest analysis for Goldman Sachs Group.

Momentum around Goldman Sachs isn’t just headline-driven. The stock’s year-to-date share price return of 43.67% really stands out, especially as it recently reported Q3 earnings ahead of expectations and completed a string of new fixed-income offerings. Investor sentiment looks increasingly favorable, with the 38.5% total shareholder return over the past year and a remarkable 286% total shareholder return over five years both reflecting renewed optimism about Goldman’s growth trajectory and resilience as economic conditions shift.

If you want to see other financial sector names with momentum and strong insider alignment, now is a great time to discover fast growing stocks with high insider ownership

Despite these impressive numbers, investors are left wondering whether Goldman Sachs shares are still undervalued given the company’s operational momentum, or if the current price already reflects all the growth investors can expect.

Compared to the last closing price, the most followed narrative values Goldman Sachs at just below current trading levels. This suggests that any future upside may depend more on continued execution than on a change in valuation.

Record growth and momentum in Asset & Wealth Management, including strong fee-based net inflows for 30 consecutive quarters and rising demand for alternative assets from high-net-worth and institutional clients, are shifting the revenue mix toward less volatile, high-margin streams. This supports higher and more durable net margins.

Read the complete narrative.

Curious what financial levers drive this precise valuation? The answer lies in a combination of analyst forecasts, management of margins, and the potential durability of future revenues. If you want to know which trends really influence the fair value for Goldman Sachs, you need to see the numbers that shaped this narrative.

Result: Fair Value of $802.53 (OVERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, persistent geopolitical tensions or unexpected regulatory shifts could quickly undermine current optimism about Goldman’s projected earnings and valuation.

Find out about the key risks to this Goldman Sachs Group narrative.

While market multiples point to Goldman Sachs being slightly overvalued compared to its peers, our DCF model, which estimates fair value based on future cash flows, suggests a very different picture. The stock is trading well above its intrinsic value of $498.31. This gap raises questions: is the optimism reflected in the share price really justified, or is the market overlooking risks?

Look into how the SWS DCF model arrives at its fair value.

If you would rather draw your own conclusions or take a closer look at the numbers yourself, it’s easy to construct a personal narrative in just a few minutes. Do it your way

A good starting point is our analysis highlighting 5 key rewards investors are optimistic about regarding Goldman Sachs Group.

Act now and give yourself the best chance to find tomorrow’s standout stocks. Missing out could mean overlooking the next big winner in your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Shanghai Henlius Biotech (SEHK:2696) shares have caught investors’ attention following recent trading activity. Although the company did not issue any formal announcements, the stock’s movements this week invite a closer look at the drivers behind its current valuation.

See our latest analysis for Shanghai Henlius Biotech.

This week’s surge has propelled Shanghai Henlius Biotech further into the spotlight, with short-term momentum helping to reverse some of the volatility seen over the past quarter. While the share price has pulled back 1.36% in the last day, it is still up 8.23% for the week and stands out with a remarkable year-to-date share price return of 193.83%. In the bigger picture, long-term investors have enjoyed a stellar 221.16% total shareholder return over the past year, reflecting both capital gains and income. The stock’s strong run suggests renewed optimism about its growth potential and market position.

If the recent rally in biotech has sparked your curiosity, consider expanding your search with our healthcare stocks screener See the full list for free.

Yet with this impressive rally and the stock currently trading nearly 47% below consensus analyst targets, investors are left to wonder whether Shanghai Henlius Biotech remains undervalued, or if the market is already factoring in all future growth.

Shanghai Henlius Biotech is currently trading at a price-to-earnings (P/E) ratio of 41.4x, putting the stock above both the industry and peer averages. With a last close price of HK$69.05, investors are paying a premium compared to other Asian biotech companies.

The P/E ratio measures how much investors are willing to pay today for a dollar of future earnings. In high-growth industries like biotech, a higher P/E can sometimes be justified if the market expects rapid profit expansion. However, this figure should be weighed against the company’s actual growth prospects and risks.

Shanghai Henlius Biotech’s P/E ratio exceeds the Asian Biotechs industry average of 40.8x and the peer group average of 37.9x. Even when considering the estimated fair P/E ratio of 23.5x, the current valuation remains elevated, suggesting the market is pricing in strong future growth or other catalysts. Significant deviation from the fair ratio could mean the market expects exceptional performance, or it may signal over-optimism that could correct.

Explore the SWS fair ratio for Shanghai Henlius Biotech

Result: Price-to-Earnings of 41.4x (OVERVALUED)

However, slower than expected revenue growth or increased competition could quickly undermine the optimism currently reflected in Shanghai Henlius Biotech’s share price.

Find out about the key risks to this Shanghai Henlius Biotech narrative.

While the market assigns a premium price-to-earnings ratio to Shanghai Henlius Biotech, our DCF model reaches a different conclusion. The SWS DCF model indicates the shares are trading about 45.5% below their fair value. This suggests the stock may be undervalued on a cash flow basis. Could the market be missing something, or is it simply cautious about future growth?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Shanghai Henlius Biotech for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 914 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

If you think there’s another angle to Shanghai Henlius Biotech’s story, you can dive into the numbers and craft your own perspective in just a few minutes. Do it your way

A great starting point for your Shanghai Henlius Biotech research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Missing out on new opportunities could mean leaving gains on the table. Turn the latest market insights into action with these hand-picked stock ideas:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include 2696.HK.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com